The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. STOCKS ON THE MOVE-Apple, SunEdison, HMS Holdings, Abercrombie

Mon, 24th Aug 2015 17:10

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)U.S. stock indexes were down on Monday. The Dow Jones industrialaverage was down 0.76 percent at 16,333.98, the S&P 500 was down 0.96 percent at 1,952.06 and the NasdaqComposite was down 0.92 percent at 4,662.53.

For a Breakingviews column, Investors' self-doubt worsensequity woes

** APPLE INC, $108.0301, +2.15 pct

The iPhone maker's shares rebounded sharply off day's lows,helping U.S. stocks stage a dramatic recovery. The shares openedmore than 10 percent lower in heavy trading. Stock still off afifth from February's record high.

For a Breakingviews column, Tech's real China syndromevictims are yet to fall

** BANK OF AMERICA CORP, $15.96, -0.87 pct

** CITIGROUP INC, $52.42, -2.20 pct

** MORGAN STANLEY, $33.47, -2.16 pct

** JPMORGAN CHASE & CO, $62.78, -1.29 pct

** GOLDMAN SACHS GROUP INC, $186.43, -0.70 pct

** WELLS FARGO & CO, $53.05, -1.70 pct

U.S. bank stocks continued to slide after last week's Fedminutes suggested the central bank may not raise interest ratesin September due to international developments, including weakeryuan.

Traders now see a 24 percent chance that Fed will increaserates in September, down from 30 percent late on Friday and 46percent a week earlier, according to Tullett Prebon data.

** NETFLIX INC, $106.57, +2.51 pct

** GENERAL MOTORS CO, $28.77, -2.80 pct

** TESLA MOTORS INC, $229.73, -0.45 pct

** CATERPILLAR INC, $74.67, -0.44 pct

** UNITED STATES STEEL CORP, $16.09, +1.13 pct

** ALCOA INC, $8.53, -2.29 pct

** YUM BRANDS, $78.61, -1.37 pct

Shares of U.S. companies fell at the open on China worries,though a handful of tech stocks were fighting against thebroadly weak market.

** SOLARCITY, $46.8701, +14.35 pct

** SUNEDISON INC, $11.61, +8.30 pct

The stocks snapped back from sharp plunges, with SolarCityup 11.5 percent after being down 15 percent in early trading.The relief rally comes one day after hedge fund manager JimChanos of Kynikos Associates said he was "short SolarCityshares" and criticized both companies' business models.

** ALIBABA GROUP HOLDING LTD, $66.92, -1.85 pct

** JD.COM INC, $24.765, -1.14 pct

** BAIDU INC, $144.395, -5.57 pct

** SINA CORP, $35.28, -2.65 pct

** YOUKU TUDOU, $16.18, -3.75 pct

** YY INC, $54.96, -7.19 pct

** CHINA DANGDANG, $6.3, -4.83 pct

** JUMEI INTERNATIONAL HOLDING, $10.78, -8.33 pct

U.S.-listed shares of Chinese technology companies fellafter Chinese indexes post their biggest one-day percentagelosses since the height of the financial crisis.

** EXXON MOBIL CORP, $70.82, -1.82 pct

** CONOCOPHILLIPS, $44.77, -1.37 pct

** CHEVRON CORP, $74.94, -1.08 pct

Oil prices fell more than 6 percent to fresh 6-1/2-year lowsas markets worried about a China-led global economic slowdownthat would drastically hit oil consumption at a time ofplentiful supply.

S&P 500 oil & gas, oilfield services companies havealready lost about $310 billion in market value this year.

For a Breakingviews column, Oil has room to get even moreirrational

** GLAXOSMITHKLINE PLC, $1,270.53703, -3.21 pct

** MERCK & CO, $54.81, -1.72 pct

** JOHNSON & JOHNSON, $95, -0.59 pct

** BIOGEN INC, $294.82, -0.28 pct

** CELGENE CORP, $118.59, -0.39 pct

** ELI LILLY & CO, $82.76, -2.09 pct

** BRISTOL-MYERS SQUIBB CO, $60.88, -0.31 pct

** PFIZER INC, $33.21 -0.98 pct

** AMGEN INC, $153.58 -1.04 pct

** GILEAD SCIENCES INC, $106.08 +0.71 pct

The S&P 500 Healthcare sector index declined 3percent to 801.97, Nasdaq Biotechnology index down nearly4 percent at 3436.71

** OCATA THERAPEUTICS INC, $4.5816 +20.25 pct

The drug developer awarded Small Business InnovationResearch grant from National Institute of Allergy and InfectiousDiseases, part of National Institutes of Health.

** EPIZYME INC, $18.9 +18.64 pct

The drug developer said U.S. Food and Drug Administrationaccepted its application to start clinical studies of its leadcancer drug, Tazemetostat.

** HMS HOLDINGS CORP, $10.73 +21.38 pct

The New York State Office of the Medicaid Inspector Generalawarded the healthcare facility provider a contract for Medicaidthird-party liability match and recovery services.

** HUBBELL INC, $113.25 +22.68 pct

The electrical equipment maker said it plans to reclassifycommon stock to eliminate its existing two-class structure.

** GEVO INC, $2.54 +10.92 pct

The chemical maker and Butamax Advanced Biofuels LLC, ajoint venture between BP and DuPont, ended apatent dispute related to the production of bio-based fueladditive, isobutanol, and entered into cross-license andsettlement agreements.

** ABERCROMBIE & FITCH CO, $17.58 +6.87 pct

Piper Jaffray upgrades the apparel retailer's stock to"overweight" from "neutral" and raises price target by $2 to$27.

** AGL RESOURCES INC, $62.01, +29.57 pct

** SOUTHERN CO, $44.58, -2.66 pct

Power producer Southern said it would buy AGL Resources forabout $8 billion in cash to become the No. 2 U.S. utility bycustomers after Exelon Corp.

** VITAL THERAPIES INC, $4.02, -77.26 pct

The drug developer said it would stop two ongoing trialstesting its cell-therapy, ELAD, after it failed a late-stagestudy in liver failure patients.

** CHINACACHE INTERNATIONAL HOLDINGS LTD, $6.02,+7.69 pct

The China-based network service provider plans to buy backup to $6 million worth of outstanding ADSs over the next 12months. This is in addition to ChinaCache's existing $10 millionshare buyback.

** EXELIXIS INC, $5.455, +3.90 pct

The U.S. FDA granted the drugmaker's lead drug,cabozantinib, "breakthrough therapy" status to treat patientswith the most common form of kidney cancer.

(Compiled by Arunima Banerjee in Bengaluru; Editing by SrirajKalluvila)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.